You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: Dec 11, 2025

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Marlid Cruz-Ramos1,2, Yessica Zamudio-Cuevas3, Daniel Medina-Luna3,4
1Oncology Translational Laboratory, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain. marlid.cruz@gmail.com.
Afatinib demonstrates significant activity in osteosarcoma cell lines, indicating its potential as a therapeutic agent for this bone cancer. Further research is warranted to explore its clinical efficacy.
Area of Science:
Context:
Purpose:
Summary:
Impact: